CJC-1295 Dosing & Protocols — Research Reference

CJC-1295 is a synthetic 30-amino-acid analogue of GHRH(1-29). The molecule exists in two forms — with the Drug Affinity Complex (DAC) lysine-maleimide attachment that binds endogenous albumin (extending half-life to ~6–8 days) and without DAC (modified GRF 1-29, half-life ~30 minutes). The two forms have very different dosing schedules.

Reconstitution for Research

CJC-1295 is supplied lyophilized in 2 mg or 5 mg vials. A 2 mL reconstitution with bacteriostatic water yields 1 mg/mL (2 mg vial) or 2.5 mg/mL (5 mg vial). At 1 mg/mL, 10 IU on a U-100 syringe delivers 100 mcg. Refrigerate reconstituted material at 2–8 °C; published stability for both DAC and no-DAC forms in bacteriostatic water typically exceeds 30 days when shielded from light.

Reference Dose Ranges in Published Research

CJC-1295 with DAC

| Research model tier | Typical range | Notes | |---|---|---| | Entry / characterization | 1 mg per week | Observable sustained GH/IGF-1 elevation in primate and human PK studies | | Standard | 2 mg per week (split twice weekly) | Most cited; produces sustained GH-pulse amplification | | High-dose pharmacology | 2 mg twice weekly | Used in IGF-1 dose-response studies |

CJC-1295 without DAC (Modified GRF 1-29)

| Research model tier | Typical range | Notes | |---|---|---| | Entry | 100 mcg per pulse | Threshold dose for GH-pulse characterization | | Standard | 100–200 mcg per pulse, 2–3× daily | Most cited; paired with a GHRP | | High-dose | 200–300 mcg per pulse | Used in acute pulse-amplitude studies |

Scheduling

With DAC: once- or twice-weekly subcutaneous injection. The albumin-bound depot produces a continuous "GH bleed" — interpreted as sustained low-amplitude pulse facilitation rather than discrete pulses. This pattern abolishes the natural circadian GH rhythm in most models.

Without DAC: 2–3 times per day subcutaneous injection on an empty stomach. The short half-life produces discrete pulses that preserve natural GH architecture and synergize cleanly with co-administered GHRPs.

Synergistic Stacking with GHRPs

Both forms are commonly paired with a GHRP (ipamorelin, GHRP-2, GHRP-6, or hexarelin). GHRH and ghrelin receptors converge on somatotrope cAMP/calcium signalling, producing synergistic GH release. The most replicated co-administration uses no-DAC CJC-1295 at 100 mcg with ipamorelin at 100–300 mcg per pulse, 2–3 times per day.

Quality and Identity Verification

Mass-spec (LC-MS) confirmation of molecular weight — 3367.85 Da (with DAC) or 3367 Da minus the maleimide-lysine for no-DAC — plus HPLC purity ≥98% are the most-cited acceptance criteria. DAC vs no-DAC identity should be confirmed by mass match because the visual presentation is identical.

Research Use Only. All content is for laboratory research and educational reference. Compounds discussed are not intended for human or veterinary consumption, prophylactic, or therapeutic use.

References

1. Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799–805.
2. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792–4797.
3. Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev. 2018;6(1):45–53.